| Author | Weld, Ethel D. | |
| Author | Parsons, Teresa L. | |
| Author | Gollings, Ryann | |
| Author | McCauley, Marybeth | |
| Author | Grinsztejn, Beatriz | |
| Author | Landovitz, Raphael J. | |
| Author | Marzinke, Mark A. | |
| Access date | 2023-05-24T19:21:20Z | |
| Available date | 2023-05-24T19:21:20Z | |
| Document date | 2023 | |
| Citation | WELD, Ethel D. et al. Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots. Journal of Pharmaceutical and Biomedical Analysis, v. 10, p. 1-10, May 2023. | en_US |
| ISSN | 0731-7085 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/58645 | |
| Sponsorship | This work was partially supported by the Johns Hopkins University Center for AIDS Research (CFAR; P30AI094189); Dr. Weld received a CFAR Scholar Award in support of this work. Dr. Weld is also supported by an NIH K23 mentored career award under award number K23AI165290. This work was also partially supported by the HIV Prevention Trials Network Laboratory Center, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Mental Health (NMH), and the National Institute of Drug Abuse (NIDA), Office of AIDS Research, of the National Institutes of Health (NIH), Department of Health and Human Services (DHHS), grant UM1- AI068613. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. | en_US |
| Language | eng | en_US |
| Publisher | Elsevier | en_US |
| Rights | restricted access | |
| Title | Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots | en_US |
| Type | Article | |
| DOI | 10.1016/j.jpba.2023.115307 | |
| Abstract | Background: Dried blood spots (DBS) have been utilized as a blood plasma alternative for therapeutic drug monitoring and pharmacologic analysis. There are analytical and physiochemical considerations in bridging drug concentrations from plasma to DBS. Recently, the long-acting antiretroviral cabotegravir (CAB) has been approved for HIV prevention, and a co-packaged regimen of long-acting CAB and rilpivirine (RPV) has been approved for HIV treatment. Measurement of these drugs in blood collected as DBS may offer increased capacity and flexibility in translational applications. Methods: Whole blood was spiked with CAB and RPV and spotted on DBS cards. Following extraction and addition of isotopically labeled internal standards, samples were subjected to liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis. The method was validated according to regulatory recommendations, and the assay was evaluated in remnant samples from an HIV prevention trial in which paired DBS and plasma samples were collected. Results: DBS CAB and RPV concentrations were linear from 25 to 20,000 ng/mL and 2-2500 ng/mL, respectively. Precision, accuracy, and matrix effect results were acceptable. DBS RPV demonstrated stability under all tested conditions; DBS CAB showed mean biases of - 23.5% when stored at room temperature for 36 days, and - 18.0% at 40 °C and 100% humidity for two days. DBS measurements for CAB and RPV were an average 54.0% and 14.1% lower, respectively, as compared to paired plasma samples. Derived conversion factors of 1.79 and 1.16 were applied to DBS CAB and RPV measurements, respectively, to estimate plasma concentrations. Estimated plasma CAB and RPV concentrations showed mean biases of 2.2% and 0.6%, respectively. In a CAB clinical trial, application of the conversion factor resulted in agreement between estimated plasma CAB concentrations from DBS and plasma CAB concentrations (y = 1.08x - 79.2, r = 0.932; mean bias of -3.2%; 95% CI: -48.2% to 41.9%). Conclusions: We developed and validated a novel LC-MS/MS assay for the quantification of CAB and RPV from DBS, and identified conversion factors to estimate plasma concentrations from spotted blood. | en_US |
| Affilliation | Johns Hopkins University School of Medicine. Department of Medicine. Baltimore, MD, USA. | en_US |
| Affilliation | Johns Hopkins University School of Medicine. Department of Medicine. Baltimore, MD, USA. | en_US |
| Affilliation | Johns Hopkins University School of Medicine. Department of Medicine. Baltimore, MD, USA. | en_US |
| Affilliation | FHI 360. Washington DC, USA. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brazil. | en_US |
| Affilliation | University of California. David Geffen School of Medicine. Center for Clinical AIDS Research and Education. Los Angeles, USA. | en_US |
| Affilliation | Johns Hopkins University School of Medicine. Department of Medicine. Baltimore, MD, USA / Johns Hopkins University School of Medicine. Department of Pathology, Baltimore, MD, USA. | en_US |
| Subject | Cabotegravir | en_US |
| Subject | DBS | en_US |
| Subject | HIV | en_US |
| Subject | LC-MS | en_US |
| Subject | Mass spectrometry | en_US |
| Subject | Rilpivirine | en_US |
| e-ISSN | 1873-264X | |
| Embargo date | 2030-12-31 | |
